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ABSTRACT
The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe
life-threatening pseudomembranous colitis. Although not always associated with previous antibiotic
exposure, it is in the majority of cases. CDAD is recognised increasingly in a variety of animal species
and in individuals previously not considered to be predisposed. C. difficile can be transmitted via
personal contact or environmentally. The role of patients and healthcare workers who are symptom-free
but colonised with C. difficile in the intestinal tract is unclear. C. difficile, with more than 150 PCR
ribotypes and 24 toxinotypes, has a pathogenicity locus (PaLoc) with genes encoding enterotoxin A
(tcdA) and cytotoxin B (tcdB). Genes for the binary toxin are located outside the PaLoc, but the role of this
toxin is unclear. The recently completed genome sequence of C. difficile 630 revealed a large proportion
of 11% of mobile genetic elements, mainly in the form of conjugative transposons. Diagnostic assays
include tests for the detection of C. difficile products or genes and culture methods for isolation of a
toxin-producing bacterium. Enzyme immunoassays to detect toxin in faeces are widely available, with
varying sensitivities and specificities. Despite practical drawbacks and sensitivity less than 100%, the
cell cytototoxicity assay is still considered to be the standard. Rapid diagnostic assays are available on a
limited scale and require much improvement. Molecular tests enable the detection of carriers of
toxigenic and non-toxigenic strains, as does culture. It is highly recommended to culture C. difficile from
toxin-positive faeces samples and to store isolates for future characterisation and typing. The financial
impact of CDAD on the healthcare system is substantial (€5–15 000 ⁄ case in England and $1.1 bil-
lion ⁄ year in the USA). Assuming a European Union population of 457 million, the potential cost of
CDAD can be estimated to be €3000 million ⁄ year, and is expected to almost double over the next four
decades. In North America, increasing rates of CDAD have been reported in Canada and the USA since
March 2003, involving a more severe course, higher mortality, increased risk of relapse and more
complications. This increased virulence is presumably associated with higher levels of toxin production
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by fluoroquinolone-resistant strains belonging to PCR ribotype 027, pulsed-field gel electrophoresis
(PFGE) type NAP1, REA (restriction endonuclease analysis) type BI and toxinotype III. In Europe,
outbreaks of CDAD due to the new, highly virulent strain of C. difficile PCR ribotype 027, toxinotype III
have been recognised in 75 hospitals in England, 16 hospitals in The Netherlands, 13 healthcare facilities
in Belgium and nine healthcare facilities in France. These outbreaks are very difficult to control, and
preliminary results from case-control studies indicate a correlation with fluoroquinolones and
cephalosporins. Information concerning community-acquired cases of ribotype 027 is lacking, and data
concerning its incidence in nursing homes are limited. European countries should first develop early-
warning and response capabilities at a national level. Depending on the nature of the notifications
received, countries should implement laboratory-based or patient-based surveillance systems in specific,
targeted populations.
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INTRODUCTION
The European Centre for Disease Prevention and
Control (ECDC) was established in 2005 by the
European Parliament and Council, with a mission
‘to identify, assess and communicate current and
emerging threats to human health from commu-
nicable diseases’. The ECDC works through
networks established among experts within the
member states of the EU. Since 2003, outbreaks of
severe nosocomial diarrhoea, caused by the new
hypervirulent Clostridium difficile PCR ribotype
027 and toxinotype III, have been recognisd in
Canada and the USA. Soon thereafter, three
European member states reported hospital out-
breaks due to an identical C. difficile strain, which
spread rapidly and involved more than 100
hospitals in total. At the initial stage, the strain
did not seem to have spread to other member
states in Europe, but recently a fourth member
state also reported an outbreak. The ECDC sub-
sequently organised meetings with experts in the
field of C. difficile infections, including experts
from the US CDC, in order to achieve a consensus
concerning this new emerging pathogen and to
discuss methods for preparedness in all European
member states. The current review represents a
summary of these findings and proposals to date.
C. DIFFICILE -ASSOCIATED DISEASE,
AN INCREASING HEALTHCARE
THREAT
Clinical spectrum
C. difficile is an anaerobic bacterium, widely dis-
tributed in soil and in the intestinal tracts of
animals. Its vegetative cells are capable of forming
spores, which confer resistance to heating, drying
and chemical agents, including disinfectants.
C. difficile was identified as the cause of pseudo-
membranous colitis and its milder form, C. diffi-
cile-associated diarrhoea, in the 1970s. The
spectrum of disease ranges from asymptomatic
carriage to a fulminant, relapsing and potentially
fatal colitis [1]. The disease is mediated by the
production of toxins of C. difficile, but there is no
correlation between the severity of the disease
and faecal toxin levels [2]. The rate of fatality
associated with C. difficile-associated disease
(CDAD) ranges from 6% to 30% when pseudo-
membranous colitis is present, and is substantial
even in the absence of colitis [1,3]. C. difficile also
appears to be an important cause of enteric
disease in a variety of animal species, including
horses, dogs, cats, birds, rodents, and especially
neonatal pigs [4], suggesting that animals may
serve as a reservoir for human pathogens.
The typical manifestations of CDAD are abdom-
inal cramps, profuse diarrhoea (mucoid, greenish,
foul-smelling and watery stools), low-grade fever
and leukocytosis [1], which may manifest several
days after antibiotic therapy is initiated, or up to 8–
10 weeks after its discontinuation [5]. Although
colitis can occur throughout the colon, it is usually
more severe in the distal colon and rectum.
However, when patients develop colitis of the
caecum and right side of the colon, they may
experience little or no diarrhoea. The clinical
presentation in this case involves fever, marked
right-sided abdominal pain, marked leukocytosis
and decreased intestinal motility.
Traditionally, CDAD has been considered to be
an antibiotic-associated nosocomial infection, but
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the role of antibiotics as predisposing factors for
CDAD can be overestimated [6,7]. Patients can
develop CDAD following numerous conditions
that affect the colonic flora, also outside the
hospital setting. The CDC have reported an
increase in severe community-acquired CDAD
in populations previously considered to be at low
risk in Philadelphia and four surrounding coun-
ties [6]. However, this observation must be eval-
uated further before recommendations for testing
of community-acquired CDAD are proposed.
Interestingly, of the 33 patients who developed
CDAD, eight (24%) reported no exposure to
antimicrobial agents within 3 months prior to
the onset of CDAD. The minimum annual inci-
dence of community-associated disease was esti-
mated to be 7.6 cases per 100 000 population or
one case per 5000 prescriptions of antimicrobial
agents for outpatients. A recent report from the
UK indicated that the incidence of C. difficile in
patients diagnosed by their general practitioners
had increased from fewer than one case per
100 000 in 1994 to 22 cases per 100 000 in 2004, but
these preliminary data require verification in this
patient population, with appropriate diagnostic
tests for CDAD and collection of clinical data [7].
Similar to experience elsewhere [6], although
antibiotic use was the most important drug-
related risk-factor for CDAD, only 37% of the
cases had received an antibiotic in the 90 days
prior to diagnosis [7].
Epidemiological characteristics
C. difficile can be cultured from the stool of 3% of
healthy adults and up to 80% of healthy new-
borns and infants [1,8]. The assumption that
C. difficile is not pathogenic for neonates and
children, based mainly on anecdotal evidence,
should be reconsidered. Stool carriage of C. diff-
icile reaches 16–35% among hospital inpatients,
with the percentage being proportional to the
duration of hospital stay and increasing with
exposure to antibiotics [3]. C. difficile persists in
the stools of 10–40% of patients with CDAD,
irrespective of the antibiotic used for treatment
[9]. Contaminated environmental surfaces, other
patients with CDAD and hand carriage on the
part of healthcare personnel are considered to be
potentially important means for C. difficile trans-
mission in hospitals [10]. Patients with CDAD are
cared for separately to minimise the spread of
C. difficile. Diarrhoea can often be unexpected and
explosive, and results in increased shedding of
C. difficile spores. Consequently, spores have been
found in far greater quantities in the environment
of CDAD patients in comparison with that of
patients who are not infected with C. difficile
[9,10]. C. difficile spores are highly resistant to
many commonly used disinfectants and may
persist for months in hospital environments [10].
It is not known whether healthcare workers and
patients with symptom-free colonisation by
C. difficile in the intestinal tract spread the bacter-
ium. The frequency of C. difficile-positive hand
culture of healthcare personnel has been shown to
correlate significantly with the intensity of envi-
ronmental contamination [11]. Clearly, good hand
hygiene practice with soap and water (rather than
alcohol hand gels) is essential in reducing the
incidence of hand carriage. The true significance
of the environment as a potential reservoir for
C. difficile and its role in subsequent patient
infection remains unclear, primarily because it
has been difficult to determine whether environ-
mental contamination is a cause or a consequence
of diarrhoea. Environmental contamination in-
volves mainly floors, including toilet floors, com-
modes and bed frames [12,13]. The bed frame was
the most common site from which C. difficile was
recovered, while the floor was the site most
contaminated in terms of total numbers of colon-
ies [12].
There is a general lack of evidence concerning
the use of detergents or disinfectants for routine
cleaning of patient areas. Routine cleaning with
detergent is often unsuccessful in eliminating
C. difficile from the environment [13]. For exam-
ple, Kaatz et al. recovered C. difficile from 31% of
ward environmental samples [14]. There is evi-
dence that contamination with C. difficile may
persist after environmental cleaning with hypo-
chlorite; disinfection with unbuffered hypochlor-
ite (500 p.p.m. available chlorine, too low to kill
spores reliably) resulted in a 21% decrease in
surface contamination levels, and this coincided
with the resolution of an outbreak of CDAD.
Phosphate-buffered hypochlorite (1600 p.p.m.
available chlorine, pH 7.6) was found to be more
effective in reducing environmental C. difficile
levels (98% reduction in surface contamination).
The results of another study found that unbuff-
ered 1:10 hypochlorite solution (5000 p.p.m.) was
effective in decreasing patients’ risk of developing
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CDAD [15]. Furthermore, in a crossover study
involving two wards for elderly patients, hypo-
chlorite-based cleaning was associated with a
reduction in both C. difficile environmental pre-
valence and the incidence of C. difficile infection
on one of the two wards [16]. However, long-term
environmental use of hypochlorite is question-
able, given its corrosive nature. The lack of
sporicidal, but environmentally friendly, disin-
fectants is a problem. Preliminary findings of a
prospective study on the effect of hydrogen
peroxide vapour (Bioquell, Andover, UK) dem-
onstrated efficacy in the eradication of C. difficile
in the environment in four intensive care wards
(J. C. Boyce et al., ICAAC 2005). However, use of
hydrogen peroxide vapour is expensive, and
rooms must be vacated and sealed before use,
limiting its practicality.
Pathogenicity
Pathogenic C. difficile organisms release two po-
tent toxins that ultimately mediate diarrhoea and
colitis [1]. These large exotoxins, toxin A (TcdA), a
308-kDa enterotoxin, and toxin B (TcdB), a 270-
kDa cytotoxin, exhibit an overall homology of
approximately 63% at the amino acid level [17]
(Fig. 1). Most enteropathogenic strains produce
both toxins simultaneously. It is suggested that
TcdA and TcdB work synergistically, based on the
fact that a TcdB effect is dependent on tissue
damage brought about by TcdA. TcdA has been
regarded as the most important factor in diarrho-
eal disease, but an increasing number of reports
show disease caused by TcdA-negative strains,
thereby implying a more important and TcdA-
independent role of TcdB in pathogenesis. In
recent years, epidemics due to TcdA-negative
strains have been described [18,19]. Additionally,
a binary toxin of C. difficile is currently being
studied as a possible new virulence marker
[20–22]. This binary toxin, an actin-specific ADP-
ribosyltransferase, can be present in up to 10% of
C. difficile strains, but its prevalence is influenced
by the selection of strains [20–22]. The binary
toxin is encoded by the cdtA gene (the enzymic
component) and the cdtB gene (the binding
component) [20,21]. The extent to which this toxin
contributes to the pathogenicity of C. difficile is
unknown; however, the C. difficile strain in which
the binary toxin was first detected caused severe
pseudomembranous colitis. Recently, Geric et al.
reported that TcdA- and TcdB-negative, but
binary toxin-positive, C. difficile strains caused
fluid accumulation in the rabbit ileal loop assay
but did not lead to diarrhoea or death in the
Fig. 1. Schematic presentation of
three toxins produced by Clostridium
difficile and their coding regions [73].
(a) Toxin A (TcdA) and toxin B
(TcdB) are encoded on the large
chromosomal region PaLoc, which
encompasses two toxin genes (tcdA
and tcdB) and three additional genes
coding for regulatory and putative
transport functions (tcdR,E,C). In
non-toxigenic strains, PaLoc is
replaced by a 115-bp sequence. On a
protein level, TcdA and TcdB
sequences are 63% homologous,
and both are large, single-chain
proteins with three functional
regions involved in toxic effects,
translocation and cell binding. (b)
Binary toxin CDT is coded by a
separate region with two genes
(cdtA and cdtB). On a protein level,
binary toxin is composed of two
protein chains that are not linked
but are both involved in toxic
effects.
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widely used hamster model [23]. The effect of
binary toxins on the intestinal tract of other
animals, e.g., horses and young calves, is
unknown.
The complete genome sequence of the multi-
drug-resistant and virulent C. difficile strain 630
was published recently [24]. The genome of 630
consists of a circular chromosome of 4 290 252 bp
and a plasmid of 7881 bp. The chromosome
encodes 3776 predicted coding sequences. The
plasmid encodes 11 predicted coding sequences,
but without obvious function. A large proportion
of the genome (11%) consists of mobile elements,
putatively responsible for antimicrobial resist-
ance, virulence, host interactions and surface
structures. Interestingly, genes involved in spore
germination (GerA family of germinant receptors)
in other clostridia and Bacillus species were not
found in C. difficile, suggesting that the germina-
tion process in C. difficile is rather unique.
Diagnostics
The diagnosis of CDAD requires the detection of
C. difficile toxins or toxin-producing C. difficile in a
diarrhoeal stool specimen. Diagnostic assays can
be divided into tests for the detection of C. difficile
products (e.g., glutamate dehydrogenase, volatile
fatty acids, toxins), tests for the detection of
C. difficile genes (16S rRNA, toxin genes) and
culture methods for the isolation of a toxin-
producing bacterium [25]. A European survey of
diagnostic methods for C. difficile revealed
marked discrepancies among laboratories and
among countries in the methods and strategies
for the diagnosis of C. difficile [26]. Culture of
toxigenic C. difficile requires at least 4 days before
results are available and has therefore no imme-
diate diagnostic value. As non-toxigenic strains
exist, cultured C. difficile must be tested for toxin
production. Cultured isolates are necessary for
typing, and culturing C. difficile from faecal sam-
ples is easy to implement in the routine setting of
diagnostic laboratories. Results of antimicrobial
susceptibility testing of the isolates are indicative
for certain PCR ribotypes, such as 027. It is
therefore highly recommended to culture C. diff-
icile from toxin-positive faecal samples. Isolates
should be stored in the local laboratory for future
characterisation and typing studies.
Toxins of C. difficile can be detected either by
virtue of their biological properties (cell cytotox-
icity assay) or by immunological methods (latex
agglutination, immunoassay). The cell cytotoxic-
ity test remains the standard by which other tests
are measured [1,16,25,27–30] but suffers from
some drawbacks. The laboratory requires a sup-
ply of cultured cell monolayers, and the results
are known to vary according to the cell line,
dilution factors, reagents used and storage con-
ditions. Additionally, the turnaround time is very
slow, typically 24 h to demonstrate cytotoxicity
and a further 24 h to neutralise this cytotoxicity.
Enzyme immunoassays (EIAs) are easier to per-
form and provide rapid results. Two types of
immunoassay have been developed: conventional
EIAs and a membrane immunochromatography
test. Numerous publications have compared the
performance of different kits for EIAs, but no
meta-analysis has been performed in an attempt
to demonstrate the superiority of a particular test.
The National C. difficile Standard Group in the UK
recommend the use of EIAs that detect both TcdA
and TcdB, because of an increasing awareness of
TcdA-negative ⁄TcdB-positive strains [18,19,28]. A
second generation of tests has been put on the
market recently. The principal advantage of the
membrane immunochromatography assay is
speed, since results can usually be obtained
within 15–30 min. Another advantage is the sim-
plicity of the assay, which does not require a high
level of technical skills. Recently, a new rapid
immunoassay (Immunocard toxins A and B,
Meridian Bioscience Europe, Boxtel, The Nether-
lands) has been compared with an in-house real-
time PCR in a prospective multicentre study
using the cytotoxicity test as the standard [29]. It
was concluded that the new rapid immunoassay
is a quick and easy-to-perform test for the
diagnosis of CDAD, but that the performance
could be improved. Some unpublished data sug-
gest that the presence of blood in the stools may
result in a false-positive result. The detection of
C. difficile gene sequences in stool samples has
focused on 16S rRNA and toxin genes [31– 33]. An
important disadvantage of the 16S rRNA ap-
proach is that non-toxigenic, as well as toxigenic,
strains are detected. Therefore, more attention
was given to the tcdA and tcdB genes of C. difficile
and a successful approach was published in 1993
[32, 33]. Real-time PCR results can be obtained
within a working day, which is shorter than the
time required for the cytotoxicity assay [29,31].
Also, the hands-on time is markedly less than that
6 Clinical Microbiology and Infection, Volume 12 Supplement 6, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 6), 2–18
required for other methods, negating the need for
post-PCR analysis. Other advantages of real-time
PCR are the low risk of carryover contamination
and the fact that it will also detect asymptomatic
carriers.
Impact on healthcare
CDAD is primarily a potentially severe nosoco-
mial infectious disease that can be prevented by
robust infection control practice. CDAD is cur-
rently the most frequently occurring nosocomial
infection in some European hospitals, e.g., in the
UK, and has the potential to become the most
frequent in others if appropriate surveillance,
prevention and control measures are not imple-
mented. In the UK, for instance, twice as many
deaths were attributed to C. difficile in 2003 as
were attributed to methicillin-ressitant Staphylo-
coccus aureus. An increase in death-associated
CDAD has also been reported recently. The
number of cases in which C. difficile either contri-
buted to the death or was the underlying cause of
death was 2.3 times higher in 2004 than in 1999
[34]. The organism is resistant to various antibi-
otics, and capitalises on the ensuing disruption of
the normal intestinal flora to colonise and cause
disease. Several factors have contributed to the
worrying escalation in the incidence of CDAD.
The elderly and immunocompromised are partic-
ularly at risk, with 80% of cases occurring in
individuals over 65 years of age. The proportion
of the population in these high-risk groups is
increasing with the general ageing of the popu-
lation in Europe. Publications from Spain over the
past several years that have reported clones
apparently resistant to metronidazole or vanco-
mycin are of concern [35,36], and very recently,
metronidazole resistance has also been observed
in Israel [37].
The impact of CDAD in healthcare settings is
considerable. Patients require isolation, revised
supportive therapy for underlying disease as well
as for CDAD, specific therapy to eliminate C. diff-
icile, scrupulous hygiene in patient care, environ-
mental decontamination, and, in the case of
outbreaks, cohort isolation and ward closure.
Reports indicate that such patients spend from 1
to 3 additional weeks in hospital. In terms of cost,
this translates into €5–15 000 per case in England
and $1.1 billion per year in the USA [38–41].
Taking the latest incidence figures from the
mandatory surveillance programme in England
(44 488 in 2004) and allowing for 3% annual
inflation since 1996, the cost of management of
CDAD in England can be estimated at €340 mil-
lion per annum. Assuming a population for the
EU of 457 million, the potential cost of CDAD can
be estimated at €3000 million per annum. More-
over, as CDAD is a disease occurring predomin-
antly among the elderly, these costs are expected
to rise as the proportion of the European popu-
lation over 65 years of age increases. The latest
figures from Eurostat (the statistical bureau for
the EU) indicate that the proportion of individu-
als over 65 years of age is expected to almost
double over the next four decades, from 75.3 mil-
lion in 2004 to 134.5 million in 2050.
EMERGENCE OF C. DIFFICILE PCR
RIBOTYPE 027 , PULSED-FIELD GEL
ELECTROPHORESIS (PFGE) TYPE
NAP1 , REA TYPE BI , TOXINOTYPE II I
IN CANADA AND THE USA
The rate and severity of CDAD is increasing in
both the USA and Canada, and may be associated
with a new strain of C. difficile marked by
increased virulence and ⁄ or resistance. Since
March 2003, outbreaks of severe cases of CDAD
have been reported in hospitals in Montreal and
southern Quebec, with an increased risk of relap-
ses [42–44]. In 2004, institutions in the region of
Quebec experienced a sharp rise in the incidence
of CDAD, involving more than 14 000 patients
[39,44,45]. In January 2005, 30 hospitals in Quebec
reported rates of nosocomial CDAD five-fold
greater than the historical average. A new, more
virulent variant (ribotype 027) strain was associ-
ated with this increase, which prompted the
government of Quebec to reserve €13.7 million
to combat CDAD in hospitals and nursing homes
[46]. Guidelines for surveillance studies and for
prevention and control of CDAD were also
formulated [47,48]. A study conducted in 2004 at
12 hospitals in Quebec included a total of 1703
patients with 1719 episodes of nosocomial CDAD
[49]. The estimated incidence was 22.5 cases per
1000 admissions, with a 30-day attributable mor-
tality rate of 6.9%. Both incidence and mortality
increased with increasing age. Compared with
matched controls, patients with CDAD seem
more likely to have received fluoroquinolones
(OR 3.9; 95% CI 2.3–6.6) or cephalosporins
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(OR 3.8; 95% CI 2.2–6.6). However, in this study,
patients with CDAD received antibiotics more
frequently and 46% more antibiotics per case (1.9
vs. 1.3) than did controls (both p < 0.0001), and
duration of antimicrobial treatment was not
examined [50]. The most common strain, which
was resistant to fluoroquinolones, was identified
in 82.2% (129 ⁄ 157) of patients. In addition, 84.1%
(132 ⁄ 157) of isolates had binary toxin genes as
well as partial deletions of the tcdC gene [49]. As
of June 2006, the strain has spread to seven
provinces in Canada, with the highest incidence
in Quebec at 13 per 1000 admissions. Quebec also
has the highest case fatality rate at 7.9% [51].
The CDC reported a steady increase in the
incidence of CDAD, from 2.7 per 10 000 hospital
admissions in 1987 to 4.2 in 2001, and have
subsequently proposed standardisation of defini-
tions and notification of CDAD [52,53]. The
number of US hospital discharges for which
CDAD was listed among the diagnoses doubled
between 1996 and 2003 [53]. A study of isolates
from the USA revealed that a previously uncom-
mon strain of C. difficile, resistant to fluoroquino-
lones and also manifesting genetic variation, was
responsible for geographically dispersed out-
breaks [54,55]. The US study collected 187 C. diff-
icile isolates from eight healthcare facilities in six
states in which CDAD outbreaks had occurred
between 2000 and 2003 [54]. At least half of the
specimens from five of the eight facilities be-
longed to REA group BI and PFGE type NAP1.
BI ⁄NAP1 isolates were positive for the CDT
binary toxin, had a deletion in the tcdC locus
and produced higher amounts of TcdA and TcdB
[56]. Resistance to moxifloxacin and gatifloxacin
was more common among BI ⁄NAP1 C. difficile
isolates than among other types (100% vs. 42%,
p < 0.001). None of the historic BI ⁄NAP1 isolates
was resistant to moxifloxacin and gatifloxacin.
The CDC also reported the strain to be associated
with high rates of morbidity and mortality
during outbreaks in hospitals in at least 11 states
[54] (http://www.cdc.gov/ncidod/dhqp/index.
html). Only two isolates were recovered from
the patients involved in the CDC report of an
increase in severe community-acquired CDAD in
populations previously considered to be at low
risk in Philadelphia and four surrounding coun-
ties [6] and, although toxin variant, these two
isolates were not BI ⁄NAP1. The minimum annual
incidence of community-associated disease was
estimated as 7.6 cases per 100 000 population or
one case per 5000 outpatient antimicrobial pre-
scriptions.
EMERGENCE OF C. DIFFICILE PCR
RIBOTYPE 027 , TOXINOTYPE II I IN
EUROPE (UK, BELGIUM, FRANCE
AND THE NETHERLANDS)
The Communicable Diseases Surveillance Centre
(CDSC) for England and Wales noticed that the
number of CDAD notifications had risen from
1000 in 1990 to 15 000 in 2000 and 35 500 in 2003,
with PCR ribotype 027 being very rare. A recent
health statistic report on the deaths involving
C. difficile in England and Wales also revealed an
increase from 975 in 1999 to 2247 in 2004 [34]. This
report examined trends in those deaths that
involved C. difficile as a contributory factor using
the specific ICD-10 code A04.7. Among deaths
that occurred in National Health Service (NHS)
general hospitals and nursing homes, CDAD
accounted for up to 0.52% and 0.45%, respect-
ively. Most of the deaths involved individuals
aged 65 years or older, and usually those who
were already very ill as a consequence of under-
lying disease. In the period between October 2003
and June 2004, the PCR ribotype 027 strain was
recognised in the UK at the Stoke Mandeville
Hospital (Buckinghamshire Hospitals NHS Trust)
in an outbreak involving 174 cases and 19 (11%)
deaths that were definitely or probably due to
C. difficile. A second outbreak occurred between
October 2004 and June 2005 in Stoke Mandeville
hospital involving 160 new cases and 19 (12%)
further deaths [57,58]. The Healthcare Commis-
sion investigation concluded that the outbreaks
were a consequence of a poor environment for
patient care, poor practice in the control of
infection, lack of facilities to isolate patients and
insufficient priority being given to the control
of infection by senior managers (report available
at http://www.healthcarecommission.org.uk/).
Shortly thereafter, the Royal Devon and Exeter
Hospital submitted 18 representative isolates of
C. difficile with a history of an outbreak that
coincided with a change of antibiotic regimen to
moxifloxacin for the treatment of patients with
community-acquired pneumonia; almost all were
type 027. As of April 2006, 450 isolates of type 027
had been referred to the Anaerobe Reference
Laboratory in Cardiff from 75 hospitals. Some
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were from clinically recognised outbreaks, and
others were routinely submitted as part of the
mandatory surveillance programme for CDAD in
England.
In July 2005, the medical microbiological labor-
atory at the Leiden University Medical Centre
was requested to type C. difficile strains from an
outbreak in a hospital in Harderwijk [59–61]. The
incidence of CDAD in the hospital had increased
from four cases per 10 000 patient admissions in
2004 to 83 per 10 000 in the months April–July
2005. Cultured isolates were subsequently identi-
fied as toxinotype III and PCR ribotype 027.
Measures taken by the hospital included isolation
of all patients with diarrhoea, cohorting of all
C. difficile-infected patients on a separate ward,
banning of all fluoroquinolone use and limitation
on the use of cephalosporins and clindamycin. In
January 2006, the situation appeared to be under
control, as the number of positive patients per
month had decreased. CDAD in all nine patients
diagnosed between September 2005 and January
2006 was caused by non-027 ribotypes. However,
a resurgence of CDAD caused by type 027 was
noticed in February 2006, when six new patients
were diagnosed. A second outbreak occurred in
another hospital 30 km from the first and was
probably related to the first outbreak through a
transferred patient with CDAD [59,60]. In this
second outbreak, 85 CDAD patients were identi-
fied by December 2005, 19 (22%) patients died
and 16 (19%) relapses were observed. In response
to the outbreaks in The Netherlands, the Centre
for Infectious Disease Control (CIb) at the
National Institute for Public Health and the
Environment (RIVM) in Bilthoven organised a
meeting with experts in the fields of microbio-
logy, infectious diseases, infection control and
epidemiology. The team agreed to make use of
those parts of existing national hospital guidelines
that were relevant for infection control in the
context of CDAD, and to use national and
international experience in drawing up specific
CDAD guidelines for infection control and treat-
ment, with separate guidelines for hospitals and
nursing homes [62]. Furthermore, diagnostic facil-
ities were increased and made accessible to all
microbiology laboratories in The Netherlands.
Relevant professionals were informed through
several communication channels, including the
various scientific societies, and plans were made
to register and monitor new outbreaks. Subse-
quently, three hospitals in the western part of the
country also reported an increase in the incidence
of severe CDAD. A nursing home in the same
region was found to harbour patients with CDAD
caused by PCR ribotype 027, with evidence of
spread within the facility. A cluster of 12 patients
with CDAD caused by PCR ribotype 027, toxino-
type III was reported in July and August 2005 in a
large teaching hospital in Amsterdam. One
patient died as a result of the consequences of
CDAD and two other patients developed severe
complications [63]. Another hospital in Amster-
dam also reported an increase in severe cases of
CDAD in July 2005 among patients who were
cared for in the department of geriatrics. Two
hospitals in the centre of The Netherlands did not
notice an increase in the incidence of patients with
CDAD, but submitted strains to the reference
laboratory for typing. Type 027 was found in six
of 17 (35%) and one of four (25%) isolates tested,
respectively [59,60]. As of April 2006, type 027
was found to be the cause of an outbreak in 11
hospitals and was isolated from sporadic cases in
five hospitals [60,64].
In September 2005, the PCR ribotype 027 strain
was isolated from four patients with CDAD in
Ieper, Belgium [65]. The incidence had increased
from 10 ⁄ 10 000 admissions to 33 ⁄ 10 000 admis-
sions in September 2005. Subsequently, the same
pattern was identified among strains from three
outbreaks that had occurred in Brussels in 2003–
2004, involving 17, six and five patients, respect-
ively. Another outbreak took place in Ostende,
Belgium, involving four patients. More recently,
14 strains were identified from a severe outbreak
in the Hospital of Libramont, Belgium. As of July
2006, type 027 had been identified as the causative
agent in outbreaks in 11 hospitals in Belgium, and
sporadic isolates of type 027 were found in two
other healthcare facilities.
On 27 March 2006, a cluster of CDAD cases was
reported to the Institut de Veille Sanitaire (InVS)
by a hospital in northern France [66]. Of 33 cases,
16 (48%) occurred in the geriatrics ward and four
were diagnosed as pseudomembranous colitis;
nine (27%) patients died within 30 days but
CDAD was not found to be the primary cause of
these deaths. On the geriatrics ward, the incidence
of CDAD rose between January and March 2006
from 13 to 116 CDAD cases per 10 000 patient-
days. Of 14 strains sent for typing, 11 were
characterised as PCR ribotype 027, toxinotype
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III. The origin of this outbreak remains unknown,
although transfers of patients between French
hospitals and Belgian nursing homes are frequent
and are under investigation [66]. The InVS
informed all French regional infection control
coordinating centres and healthcare facilities and
disseminated recommendations for reporting,
investigation, surveillance and control of CDAD.
As of August 2006, the InVS and regional
infection control coordinating centres had inves-
tigated 15 clusters of CDAD, encompassing 222
patients. Nine episodes (194 patients) were due to
type 027, all in Northern France; among these
patients, 12 (6%) deaths were attributable to
CDAD; updates about this outbreak will be
posted on the InVS web site: http://www.invs.
sante.fr/raisin/
CHARACTERISTICS OF C. DIFFICILE
PCR RIBOTYPE 027 , PFGE TYPE NAP1 ,
REA TYPE BI AND TOXINOTYPE II I
C. difficile can be divided into more than 150
ribotypes and 24 toxinotypes [55,67] (http://
www.mf.uni-mb.si/mikro/tox). Toxinotyping
involves detection of polymorphisms in the tcdA
and tcdB and surrounding regulatory genes, an
area of the genome known collectively as the
pathogenicity locus or PaLoc [68]. PCR ribotyping
is based on differences in profiles generated by
PCR amplification of the intergenic spacer regions
between the 23S and 16S rRNA genes [67,69].
The epidemic strain isolated in Canada, the
USA, the UK, Belgium, France and The Nether-
lands was characterised as PCR ribotype 027 and
toxinotype III. Strains from North America were
further characterised as PFGE type 1 and restric-
tion endonuclease analysis group type BI. Some
strains from Europe have also been typed as
PFGE type 1 and REA type BI, and it is very likely
that all PCR ribotype 027 and toxinotype III
strains belong to this REA and PFGE type. The
strain carried the binary toxin gene cdtB and had
an 18-bp deletion in tcdC. In the PCR ribotype 027
strains isolated in Canada, an additional single-
base-pair deletion was detected in the tcdC
sequence at position 117 [70].
Strains of toxinotype III (belonging to ribotypes
027, 034, 075, 080) have been found sporadically
and represent 2–3% of isolates from large collec-
tions [55,71,72]. Strains belonging to toxinotype III
produce binary toxin in vitro, but the importance
of binary toxin CDT as a virulence factor in
C. difficile has not been established [21]. The
binary toxin, an actin specific ADP-ribosyltransf-
erase, is encoded by the cdtA gene (the enzymic
component) and the cdtB gene (the binding
component), which are not located within the
pathogenicity locus [20,21]. Non-pathogenic
strains containing cdtA and cdtB, but lacking the
pathogenicity locus, are also capable of producing
binary toxin. The binary toxin is present in up to
10% of all C. difficile isolates, and is mostly
present in variant toxinotypes [20–22].
The application of restriction analysis as a
typing technique for C. difficile was reported in
1987 and subsequently standardised in 1993
[73,74]. The REA patterns are visually compared
to the restriction patterns of the reference REA
types. At least 100 groups have been recognised
by REA, and the eight most common toxigenic
REA groups are Y, B, G, L, E, J, R, N and BD. REA
group type BI, which was first identified in 1984,
was uncommon (n = 18) among isolates from the
historic database (1984–1992) of 6000 isolates [54].
PCR ribotype 027 was first assigned in 1988
from a culture collection of M. Popoff (Paris,
France) and originated from a 28-year-old woman
with severe pseudomembranous colitis. Until
March 2004, it was considered to be an unimpor-
tant and very rare PCR ribotype. The clonality of
PCR 027 is currently a topic of research. PCR
ribotype 027 exhibits two PFGE patterns with
94% similarity [54]: North American PFGE types
1a and 1b (NAP1a and NAP1b). As demonstrated
for PCR ribotype 001, other typing techniques
(DNA fingerprinting, REA, AP-PCR) may reveal
additional subgroups. Preliminary data from D.
Gerding (Chicago, USA) indicate that REA is able
to discriminate further at least 24 subtypes of BI
within PCR ribotype 027. Currently, various
typing techniques are being applied to a large
collection of strains from Canada, the UK, the
USA and The Netherlands.
The importance of the 18-bp deletion in tcdC of
the PCR ribotype 027, toxinotype III strains is also
unknown. The tcdC gene is considered to be a
negative regulator of the production of TcdA and
TcdB, but it is not known whether this 18-bp
deletion results in a non-functional product. A
recent report indicates that toxinotype III isolates
produce TcdA and TcdB in considerably greater
quantities in vitro than do toxinotype 0 isolates
[56]. The significance of these in-vitro findings to
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the understanding of in-vivo virulence remains
uncertain, since an association between faecal
toxin levels and clinical severity of disease has not
been established [2]. Also, deletions in tcdC are
frequently present in toxigenic isolates. Of 32
toxigenic strains studied in 2002, eight belonged
to toxinotypes 0, V and VI and contained dele-
tions in tcdC of 18 bp or 39 bp, without an
association with clinical severity of disease [75].
The recently discovered 117 deletion in tcdC
represents a frameshift and premature stop in
the early portion of the gene, and the downstream
effects on the functional capacity of any resulting
tcdC transcripts would constitute a major disrup-
tion of tcdC function [70].
Little information is available concerning the
sporulation characteristics and spread of
NAP ⁄ 027 into the environment, in comparison
with other types. It has been reported that
sporulation levels of outbreak type 027 strains
and outbreak type 001 exceed those of other
strains (LB-28-2005: S. Underwood et al., ICAAC
2005). The highest sporulation levels were
achieved when strains were exposed to non-
chlorine-based cleaning agents, suggesting that
the use of such cleaning agents in hospitals may
enhance the spread of CDAD.
IMPLICATIONS FOR EUROPE
DISCREPANCY AMONG METHODS AND
STRATEGIES FOR DIAGNOSING CDAD
A European surveillance study of diagnostic
methods and testing protocols for C. difficile
among 212 hospitals in eight countries in 2002
revealed marked differences among laboratories
concerning the methods and the strategies used
for diagnosing CDAD [26]. In 58% of cases,
laboratories undertook investigations for CDAD
only when specifically requested by the physi-
cian, and only 55% of the laboratories were
capable of culturing for C. difficile. These results
are also in agreement with a survey performed in
the UK by the Healthcare Commission and
Health Protection Agency among 118 NHS Trusts
in 2005, which was conducted in order to make
best use of the reported incidence of CDAD, the
reported approaches to prevention, management
and control of outbreaks, and the views of
professionals concerning prevention. Also, the
survey was undertaken to obtain information
regarding diagnostic testing and processing of
samples from suspected cases of CDAD. In 2004,
guidelines and recommendations were published
by the National Clostridium difficile Standards
Group and mandatory surveillance was intro-
duced in 2004, according to which infections in
patients aged 65 years and older were required to
be reported [28,76]. All laboratories were using a
recommended test for diagnosing CDAD, but
only 25% performed C. difficile culture. There
was considerable variation in the use of culture
and typing among different laboratories. As part
of the mandatory surveillance programme, as of
January 2005 all laboratories were required to
submit isolates of C. difficile for typing in a
structured programme. During 1 week each year,
in a consecutive programme, a particular labor-
atory is asked to send toxin-positive stool sam-
ples (up to a maximum of ten) to the Regional
Laboratory of the Health Protection Agency.
Culture of the samples is performed at the
Regional Laboratory and the isolates of C. difficile
are sent to the Anaerobe Reference Laboratory
(Cardiff, UK) for typing.
In The Netherlands, a survey conducted among
12 laboratories also revealed marked discrepan-
cies in the methods and the strategies for diag-
nostic testing. During a 3-month pilot study,
using an optimal test algorithm at four university
laboratories, a nearly 20% increase in the number
of CDAD patients diagnosed was found (unpub-
lished results). This algorithm enabled the micro-
biological laboratories to test all faecal specimens
of patients hospitalised for more than 3 days who
developed diarrhoea, irrespective of a physician’s
request. This algorithm has now been introduced
in 15 laboratories.
Incidence of CDAD in the member states of the
EU
Limited information on the incidence of CDAD is
available from a European survey involving 212
hospitals that was performed by the European
Study Group of C. difficile (ESGCD) in the UK,
France, Belgium, Denmark, Germany, Italy and
Spain in 2002 [26]. The incidence varied consid-
erably, depending on the testing strategies and
the tests applied. The incidence was 11 per 10 000
admissions. In contrast, data from studies in the
USA showed that the incidence among hospital-
ised patients is much higher, ranging from 10 to
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200 per 10 000 admissions [77]. A second Euro-
pean surveillance study was performed in 2005.
The reporting of cases in all EU member states
takes place on a voluntary basis, except in
England, where mandatory reporting was intro-
duced in 2004. The first set of results from the
mandatory surveillance scheme revealed 44 488
cases of C. difficile in those over 65 years of age in
England during 2004 [76]. Two-thirds of the
Trusts reported an increase in CDAD cases
during the past 3 years, and 25% have dedicated
a ward during the past 12 months for CDAD care.
It is very likely that these data underestimate the
real incidence of CDAD, since the surveillance
scheme was restricted to patients over 65 years of
age and to nosocomially acquired CDAD. Infor-
mation concerning the extent of CDAD in patients
in nursing or residential homes, in other health-
care facilities and in individuals under the care of
a general practitioner is lacking.
THE ROLE OF MEDICAL
MICROBIOLOGISTS, INFECTION CONTROL
PRACTITIONERS, INFECTIOUS DISEASE
SPECIALISTS AND EPIDEMIOLOGISTS IN
COMBATING CDAD
To reduce severe outcomes of CDAD, early
diagnosis and initiation of specific antimicrobial
treatment are important. Prevention of outbreaks
of CDAD in hospitals can only be accomplished
by early recognition, adequate isolation measures
and prompt treatment. Based on recent experi-
ence with epidemics of C. difficile type 027, most
microbiological laboratories are currently imple-
menting a new rapid immunoassay test as part
of routine diagnostics. Some microbiological
laboratories have developed rapid molecular
tests (real-time PCR) to diagnose CDAD. It is
expected that in the next few years microbiolo-
gical laboratories will introduce other rapid
diagnostic tests. Development of these new tests
should lead to assays with a better performance
than those currently available. The medical
microbiology laboratories have a central role in
surveillance of CDAD in hospitals and other
healthcare institutions, as well as the community,
but testing strategies and algorithms must be
well-defined.
The hospital hygiene ⁄ infection control depart-
ment plays a central role in the prevention of
nosocomial infections and thus a major role in the
prevention of CDAD by ensuring adequate isola-
tion of affected patients, institution of precautions
and formulation of practice guidelines.
The hospital hygiene team develops strategies
for hand washing, environmental hygiene and
outbreak control; however, contamination with
C. difficile spores has been demonstrated in 30–
60% of sites in hospital wards. Thus, appropriate
and adequate cleaning of the hospital environ-
ment is an important part of the programme for
prevention of CDAD. Infection control is of
special importance in an outbreak situation in
order to control transmission. Ideally, patients
with suspected or proven CDAD will be isolated,
and will be cohorted if sufficient isolation facilit-
ies are not available.
Medical microbiologists and infectious disease
professionals can play a major role in the
prevention of CDAD by reducing antibiotic
prescriptions; up to 50% of all antibiotic usage
in hospitals is inappropriate. Hospital infections
caused by antibiotic-resistant bacteria are associ-
ated with higher rates of mortality and morbid-
ity and prolonged hospital stay compared with
infections caused by antibiotic-susceptible bac-
teria. An analysis by the Cochrane Institute (19
October 2005; 4:CD003543) showed that inter-
ventions to improve and reduce antibiotic pre-
scribing to hospital inpatients are successful and
can significantly reduce antimicrobial resistance
and the incidence of hospital-acquired infections
such as CDAD.
Currently, PCR ribotyping is considered to be
the standard method for typing of C. difficile in
Europe [67,69]. Other typing methods have also
been developed and applied, but standardisation
of these methods and exchange of data among
laboratories has never been achieved. The results
of PCR ribotyping can be stored as TIFF files and,
for further analysis, imported into the BioNume-
rics software (Applied Maths, Kortrijk, Belgium).
The Anaerobe Reference Laboratory, University
Hospital of Wales, Cardiff, UK holds isolates from
all the PCR ribotypes in its database, which will
allow future epidemiological investigations at an
international level. It is possible to make this
database available on a remote access server so
that other reference laboratories will be able to
identify not just type 027 but other PCR ribotypes.
Further characterisation of the strains for the
presence of virulence markers, including genes
for TcdA and TcdB, genes for the binary toxin,
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and deletions in a toxin regulator gene (tcdC),
should be performed by the reference laboratories.
Finally, there is a need for reference laboratories
to develop new typing techniques with discrim-
inative capacities better than those currently
available.
Antibiotic susceptibility testing of C. difficile
is not routinely performed at every microbio-
logical laboratory; however, surveillance of the
antibiotic sensitivity of C. difficile is of the
utmost importance. The antibiotic of choice for
treatment of infections associated with C. difficile
is metronidazole, followed by vancomycin as a
second choice. Unfortunately, reports from some
laboratories mention the occurrence of metroni-
dazole resistance and vancomycin resistance in
C. difficile, although the exact mechanism is
unknown and confirmation of these findings
by reference laboratories is urgently needed [35–
37,78].
CONCLUSIONS OF THE WORKING
GROUP
Increased awareness of CDAD should be a
priority in all European member states
CDAD has a broad clinical spectrum and is not
always associated with previous antibiotic use.
Although CDAD presents most frequently as a
hospital-acquired ⁄nosocomial infection, recent
reports suggest an increase in community-
acquired CDAD in populations not considered
at risk. Therefore, knowledge of CDAD is of
importance for all healthcare workers.
Clear methods and strategies for diagnosing
CDAD
Guidelines for CDAD diagnostic strategies should
be formulated according to regional incidence
rates of CDAD and local laboratory capacities.
There is an urgent need for rapid diagnostic tests
with a better performance than the currently
available assays.
Interim recommendations for CDAD case
definitions are necessary
For surveillance purposes, interim case defini-
tions are proposed that focus on disease and do
not refer to a particular strain. These definitions
are based on past experiences in the USA,
Canada, the UK and The Netherlands and on
current discussions within European and US
working groups; they may evolve in the near
future.
CDAD CASE
This is a patient to whom one or more of the
following criteria applies:
1. diarrhoeal stools or toxic megacolon, and a
positive laboratory assay for C. difficile TcdA
and ⁄ or TcdB in stools or a toxin-producing
C. difficile organism detected in stool via
culture or other means;
2. pseudomembranous colitis revealed by lower
gastrointestinal endoscopy;
3. colonic histopathology characteristic of C. diff-
icile infection (with or without diarrhoea) on a
specimen obtained during endoscopy, colec-
tomy or autopsy.
This definition may be focused on criterion
no. 1 in laboratory-based surveillance systems
performing tests for C. difficile only on unformed
stools (i.e., stools that take the shape of their
container). All three criteria can be used in
patient-based surveillance systems targeting diar-
rhoeal symptoms (i.e., at least three liquid or
unformed stools for at least 24 h).
This definition excludes diarrhoea with other
known aetiology (as diagnosed by the attending
physician), and asymptomatic patients with a
stool culture positive for toxin-producing C. diff-
icile or an assay positive for C. difficile TcdA
and ⁄ or TcdB.
RECURRENT CDAD CASE
This is a patient with an episode of CDAD that
occurs within 8 weeks following the onset of a
previous episode. A recurrence can correspond to
a relapse involving the same strain or to a re-
infection with a different strain [79–82]. The
simultaneous occurrence of multiple PCR
ribotypes in faecal samples may also result in
isolation of a different strain in a recurrent
episode [83]. In clinical practice, it is not possible
to differentiate between relapse and re-infection;
the term recurrence is therefore used as a desig-
nation for both. The risk of complications in the
case of a recurrence due to the new emerging
strain may be higher than previously thought
[43].
Kuijper et al. C. difficile-associated disease 13
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 6), 2–18
SEVERE CDAD CASE
This is a CDAD patient to whom any of the
following criteria apply:
1. admission to a healthcare facility for treatment
of community-associated CDAD;
2. admission to an intensive care unit for treat-
ment of CDAD or its complication (e.g., for
shock requiring vasopressor therapy);
3. surgery (colectomy) for toxic megacolon, per-
foration or refractory colitis;
4. death within 30 days after diagnosis if
CDAD is either the primary or a contributive
cause.
OUTBREAK OF CDAD
An outbreak can be defined as the occurrence of
two or more related cases of CDAD over a
defined period agreed locally, taking account of
the background rate [28].
ORIGIN (Fig. 2)
The proposed categories are based on information
concerning the origin of CDAD (healthcare-asso-
ciated or community-associated) and the onset of
symptoms (within the context of healthcare or
within the community).
Healthcare-associated case
This is a CDAD case patient with onset of
symptoms at least 48 h (>48 h) following admis-
sion to a healthcare facility (healthcare-onset,
healthcare-associated) or with onset of symptoms
in the community within 4 weeks following dis-
charge from a healthcare facility (community-
onset, healthcare-assocciated).
Community-associated case
This is a CDAD case patient with onset of
symptoms while outside a healthcare facility,
and without discharge from a healthcare facility
within the previous 12 weeks (community-onset,
community-associated) or with onset of symp-
toms within 48 h following admission to a health-
care facility without residence in a healthcare
facility within the previous 12 weeks (healthcare-
onset, community-associated).
Unknown case
This is a CDAD case patient who was discharged
from a healthcare facility 4–12 weeks before the
onset of symptoms.
ONSET (Fig. 2)
Healthcare onset
Symptoms start during a stay in a healthcare
facility.
Community onset
Symptoms start in a community setting, outside
healthcare facilities.
NECESSITY FOR INVESTIGATION AND
REPORTING OF OUTBREAKS ON BOTH
NATIONAL AND EUROPEAN LEVELS
The definitions proposed above may be used in
implementing CDAD surveillance schemes in spe-
cific populations. Depending upon the populations
and the reasons for surveillance and reporting, all
or some of these definitions may be appropriate.
For example, in the UK (http://www.hpa.org.uk/
cdr/archives/2005/cdr3405.pdf), the population
can be restricted to patients over 65 years of age,
regardless of the presence or absence of specific
risk-factors (e.g., prior antimicrobial therapy).
Since the implementation of comprehensive
and systematic surveillance systems at the
national level in each of the European member
states will require some time, countries should
first develop early-warning and response capa-
time
Admission Discharge
Healthcare-onset Community-onset
48h 4 weeks 8 weeks
Community-associatedUnknownHealthcare-associated(*)
(*) : - may be community- or healthcare-associated, depending on case’s history.
- if healthcare-associated, may have been acquired in the same facility or imported from another.
Fig. 2. Relationship among epide-
miological definitions.
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bilities in order to detect and notify to regional or
national public health authorities severe cases of
CDAD related to the PCR ribotype 027 strain of
C. difficile.
When analysing data concerning cases that are
‘borderline’, i.e., those that could be either com-
munity- or healthcare-associated, the notification
report should indicate the most probable origin
and justify the conclusion.
The nature of the notifications received will
determine how individual countries will subse-
quently implement laboratory-based or patient-
based surveillance systems in specific, targeted
populations (e.g., patients in hospitals, patients in
nursing homes). For feedback and benchmarking
purposes, healthcare-associated case rates should
be expressed as cases per reporting time period
(e.g., month or quarter) per 1000 patient admis-
sions and per 10 000 patient-days, as the average
length of patient stay may vary from one facility
to another. Data that are separated according to
the epidemiological markers, i.e., the time period
between hospital admission and discharge, as
well as overall data will be most valuable.
Community-associated case rates should be
expressed as cases per 100000 population over
the reporting period (usually person-years).
When calculating healthcare- or community-asso-
ciated case rates, recurrence rates should be
separated from other cases.
Investigation of the incidence of CDAD 027 on
the part of EU member states
In order to gain insight into the incidence of
CDAD due to C. difficile 027 in the 12 European
member states, the ongoing surveillance study
undertaken by the ESGCD, which includes assess-
ment of the distribution of the most frequently
occurring PCR ribotypes and characterisation of
the strains for specific virulence markers and
antimicrobial susceptibility patterns, should be
completed as soon as possible. A second surveil-
lance study should be developed in which all
European member states participate and in which
the incidence of CDAD in hospitals, long-term
care facilities and the community will be deter-
mined.
Because of the epidemic potential, as well as the
severity of the burden that CDAD imposes on the
healthcare system, each EU member state should
consider instituting a national working group for
C. difficile. Such a group would encompass the
respective national institutes of health and the
epidemiologists and experts in prevention, diag-
nosis and treatment of CDAD. National reference
laboratories should be established, with which the
working group would collaborate closely.
Research priorities concerning new emerging
C. difficile
The new emerging 027 strain offers a good
opportunity to develop models for in-depth
research into the pathogenesis of CDAD. C. diff-
icile, however, has proven to be particularly
difficult to manipulate genetically. As a conse-
quence, our understanding of the pathogenesis of
infections caused by C. difficile lags well behind
that of other bacterial infections. For instance,
several putative surface adhesins and surface
layer proteins have been recognised, but their
role in pathogenesis has not been established. The
major impediment has been an inability to inser-
tionally inactivate chromosomal genes. Promising
new developments for creating insertion mutants,
as well as information concerning the crystal
structures of the two toxins, were reported at the
International ClostPath Meeting (June 2006, Not-
tingham, UK). These developments pave the way
for functional genomic studies in which the role
of putative genes in pathogenesis may be
assigned.
Although the mechanisms of action of TcdA
and TcdB are known, their individual import-
ance in the disease process is unclear. The
receptors are still unknown but could be iden-
tified in the near future by structural studies of
newly published partial crystal structures for
TcdA and TcdB [84,85]. An important area for
research is the application of new animal mod-
els, e.g., zebrafish embryos, to investigations of
the systemic action of C. difficile toxins. Addi-
tionally, the exact role of all genes encompassing
the PaLoc is not known and more information
concerning the molecular mechanism of toxin
regulation is needed. The full genome of two
C. difficile strains has been sequenced, including
the C. difficile 630 strain and the type 027 strain.
An understanding of these genomes and the
future development of microarray techniques in
the context of C. difficile have the potential to
open a new era of C. difficile research. Production
of spores may play an important role in the
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spread of CDAD, and an understanding of its
regulatory systems and intracelluar communica-
tion systems (quorum-sensing) may provide
opportunities to inhibit this process. Although
much attention has been given to virulence
factors in the context of C. difficile, innate and
acquired immunity in humans appear to play
important roles in protection. The fact that
CDAD occurs mainly in the elderly suggests
that some form of immunodeficiency may pre-
dispose, which opens another possibility for
research. The preliminary results of studies on
vaccines containing formalin-inactivated TcdA
and TcdB also demonstrate the importance of
adequate humoral immunity and call for further
studies.
CONCLUSION
In summary, CDAD due to the new emerging
C. difficile type 027 has resulted in the recognition
of CDAD as a major nosocomial infection, cre-
ating emerging threats to human health and the
community. Understanding of the pathogenicity
of the disease could lead to better prevention of
the disease in humans and animals.
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